Publications by authors named "Bror Jonzon"

Claim this Profile
T
The effect of intradermal microdosing of a transient receptor potential cation channel subfamily V member 1 antagonist on heat evoked pain and thermal thresholds in normal and ultraviolet-C exposed skin in healthy volunteers.
Erik Sjögren, Lars Ståhle, Hans Quiding, Bror Jonzon, Magnus M Halldin

Eur J Pain· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pain model with a neuropathic somatosensory lesion: Morton neuroma.
Hans Quiding, Christian Åkermark, Märta Segerdahl, Ingalill Reinholdsson, Hanna Svensson, Bror Jonzon

Pain· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction.
Hans Quiding, Bror Jonzon, Ola Svensson, Lynn Webster, Annika Reimfelt

Pain· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia.
Jarkko Kalliomäki, Nadine Attal, Bror Jonzon, Flemming W Bach, Karin Huizar

Pain· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy.
Jarkko Kalliomäki, Bror Jonzon, Karin Huizar, Michael O'Malley, Anita Andersson

Scand J Pain· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of severe pain in a cohort of 5271 individuals with self-reported neuropathic pain.
Stephen Butler, Bror Jonzon, Christina Branting-Ekenbäck, Cecilia Wadell, Bahman Farahmand

Pain· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects.
Clive H Wilder-Smith, Bror Jonzon, Bodil Fornstedt-Wallin, Ann Hedman, Pär Karlsson

Scand J Gastroenterol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo.
L Christofer Adding, Per Agvald, Lars I Andersson, Bror Jonzon, Janet Hoogstraate

Br J Pharmacol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Gunilla Huledal, Bror Jonzon, Maria Malmenäs, Ann Hedman, Lars I Andersson

Clin Pharmacol Ther· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation.
Janet Hoogstraate, Lars I Andersson, Odd-Geir Berge, Bror Jonzon, Göran Ojteg

Inflammopharmacology· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers.
Bror Jonzon, Ingvar Bjarnason, Chris Hawkey, John Jones, Andrew Goddard

Inflammopharmacology· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis